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1. Introduction
  Salmonella enterica serovar Paratyphi A is the second most 
common cause of enteric fever after Salmonella typhi with 
infection rate between Salmonella typhi to paratyphi being 
approximately 4:1. Population based studies have estimated 
the global burden of enteric fever, to be >21 million cases 
of typhoid fever in the year 2 000 and >5 million cases 
of paratyphoid fever with regions of high incidence of 
typhoid fever(>100/100 000cases/yr) at South Central Asia 
and South East Asia[1]. Typhoid and paratyphoid fever 
have only humans as reservoir, but recently the bacilli 
has been isolated from domestic animals and fish. Enteric 
fever is endemic in India and other Asian countries and is 
classically caused by Salmonella enterica serovar Typhi. 
Salmonella enterica Paratyphi A, which causes milder form 
of the disease and had been reported less frequently, hence 
very few reports on the pattern of disease by this pathogen 
are available. Since 1996, an increasing trend in isolation 
of Salmonella paratyphi A (S. paratyphi A)causing enteric 
fever has been noticed in India[2]. A rise in proportion 
of S. paratyphi A was noticed from Calicut[3], Nagpur 
(46.15%)[4], Sevagram (53.33%)[5],  Rourkela[6],  and 
Chandigarh[7]. Improved standards of public health have 
resulted in a marked decline in the incidence of enteric 
fever in developed countries[1], but is still a major public 
health problem in developing countries including India. The 
disease burden is compounded by the emerging multidrug 
resistant isolates of Salmonella[8,9]. Present study was 
undertaken to evaluate the clinical profile and changing 
susceptibility pattern to antimicrobials of S. paratyphi A 
isolates over the period of 3 years in a tertiary care hospital 
in southern India.
Objective: To review the clinical profile and drug susceptibilities of Salmonella paratyphi A 
in a tertiary care hospital. Methods: Retrospective analyses of 113 patients with paratyphoid 
fever and 101 culture proven Salmonella paratyphi A infection were included in the study. The 
study extended over a period of 3 years (2006-2008). Diagnosis of patients were based on clinical 
features, serology and blood culture. The drug susceptibility testing of the isolates were performed 
by the disc diffusion method. Clinical presentation, laboratory parameters, susceptibility patterns 
of isolates, treatment and clinical response were studied. Results: Of the 113 cases, 77 (68.4 %) 
were males and 36 were females (32.8%), which included 2 pediatric patients. Fever was the most 
common symptom (100.0%) followed by loose stools (37.2%), headache (35.4%), myalgia (31.9%), 
pain abdomen (29.2%), dry cough (19.5%) and vomiting (13.3%). All patients were clinically cured. 
Majority of the isolates (46%) were resistant to cotrimoxazole in 2006, however they became 
100% sensitive in 2007 and 2008. whereas the strains became 100% sensitive to ampicillin and 
chloramphenicol only in 2008. In 2006 the sensitivity of organisms to ciprofloxacin was 89% 
but in 2007 and 2008 there has been an increasing resistance to ciprofloxacin (46% and 86%) 
respectively . Surprisingly 3 isolates (8.1%) were resistant to ceftriaxone in 2006 , showed 100% 
sensitivity in 2008. Common drugs used were ceftriaxone in 100 cases (88.4%) and ciprofloxacin 
in 13 cases (11.6%).One patient had relapse of paratyphoid fever after treatment with ciprofloxacin 
which responded to ceftriaxone. Conclusions: Paratyphoid fever A is one of the emerging 
infections and a significant problem in India. An increasing resistance to fluoroquinolones is 
noted. Continuous monitoring of drug susceptibilities is mandatory in instituting appropriate 
therapy. 
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 4. Discussion
  Salmonella enterica serovar Paratyphi A was the less 
frequent cause of enteric fever in earlier days, with isolation 
rates being 3-17% from India. The incidence of enteric fever 
due to S. paratyphi A is increasing since 1996[2]. An increase 
in isolation of S. paratyphi A was reported with 11.1%(2001) 
to 59%(2003) from Calicut[3]. Between 2001 to 2003 an 
unusually high occurrence of S. paratyphi A infection was 
reported from Nagpur[4]. A recent study from Chandigarh 
also showed an increasing trend of isolation of S. paratyphi 
from January 2003 to April 2007[7]. Regarding the differential 
risk factors for typhoid and paratyphoid, the infections 
have distinct routes of transmission. Paratyphoid fever was 
associated with sources outside the household such as food 
from street vendors and flooding in contrast to typhoid fever 
which is mostly due to household contacts as reported by 
Vollard AM et al[10]. It is also noticed increased cases of 
paratyphoid fever among students, young population and 
males related to the eating behaviour of these people. Drug 
resistance in typhoid fever is considered as one of the most 
important factors in the morbidity and mortality of the 
disease. The quinolone group of drugs emerged as useful 
drugs for the treatment of multiple drug resistant cases of 
Salmonella typhi but unfortunately ciprofloxacin resistance 
in the S. paratyphi A isolates has been reported from various 
2. Materials and methods
  The study was carried out at Kasturba Hospital Manipal, 
Karnataka, a tertiary care hospital over a period of 3 years, 
from 2006 to 2008.
  We retrospectively analysed the records of 113 patients 
suffering from paratyphoid fever due to S. paratyphi A. 
Of the 113 patients, 77 (68%) were males and 36(32%) were 
females, which included 2 female children. The mean age 
of presentation was 29.27 years with age ranging from 6-74 
years. More number of S. paratyphi were isolated compared 
to Salmonella typhi in the year 2006 and 2007.
  Cases were diagnosed based on clinical features, isolation 
of S. paratyphi A from blood using BactT/Alert automated 
blood culture system and widal tube agglutination test. 
Widal titres O & AH > 1:160 with four fold rise were 
considered positive for paratyphi A infection. Antimicrobial 
susceptibility testing was done using Kirbey-Bauer disc 
diffusion method, according to standard guidelines for 
ampicillin, cotrimoxazole, chloramphenicol, ciprofloxacin 
and ceftriaxone. The clinical presentation, antimicrobial 
susceptibility, antimicrobial therapy, laboratory parameters, 
response to treatment and complications were recorded. 
Analysis of data was done using SPSS (11.0 for Windows) 
Defervescence was defined as the number of days required 
for abatement of fever after starting the antibiotics. Relapse 
was defined as the recurrence of fever or other clinical signs 
of infection within 2 months of completion of treatment with 
positive blood culture, after an appropriate initial clinical 
and bacteriological response.
3. Results
  Fever was the most common symptom present in all cases 
(100.0%) followed by loose stool (37.2%), headache (35.4%), 
myalgia(31.9%), pain abdomen (29.2%), dry cough (19.5%), 
and vomiting(13.3%). Hepatomegaly was found in 14(12.4%) 
cases and splenomegaly in 29(25.7%), liver function test 
abnormality was noted in 30(26.6%) cases. Thrombocytopenia 
was noticed in 19 (16.8%) patients. Of these 5 patients 
had dengue co-infection proved by IgM ELISA and had 
significantly low platelet count. 
  Blood cultures grew S. paratyphi A in 101 patients, in the 
remaining 12 cases the diagnosis was made by widal test 
which showed significant titres(>1:160 for O& AH antigen) 
with four fold rise. Among the culture positive cases ,Widal 
test showed significant titres (≥1:160 for O and AH antigen) 
in 22 patients(19.5%) and Widal test was negative in 79 
patients(70%), majority of them presented with fever less 
than one week duration.
  In our study there was evidence of other co-infection. Of 
the 12 culture positive cases with paratyphoid A cases 5 
patients were tested positive in dengue IgM ELISA. Three 
had associated urinary tract infections due to Escherich coli 
and one each were positive for HIV, hepatitis, malaria and 
leptospirosis. 
  In our study 100 patients received ceftrioxone and 
13 patients received ciprofloxacin. The mean time of 
defervescence in patients who received ciprofloxacin was 7 
days as compared to ceftriaxone group which took only 5.1 
days. One patient treated with ciprofloxacin had a relapse 
after 2 months and S. paratyphi A grown in blood culture 
which responded to ceftriaxone and declared clinically cured.
  The antimicrobial sensitivity of S. paratyphi A has changed 
over the period of 3 years.This has been depicted in Table 
1.There was a drastic upsurge of ciprofloxacin resistance 
from 2006-2008. The resistant isolates have almost increased 
by 10 fold. It is interesting to note that susceptibility 
of S. paratyphi A to ampicillin, chloramphenicol and 
cotrimoxazole (first line drugs) increased with decreasing 
resistance in 2007 and 2008. The widely used drug 
ciftriaxone, 3rd generation cephalosporin has been shown 
to be effective over years. There was no reported resistance 
to this drug in 2008 which made it the drug of choice for S. 
paratyphi A. 
Table 1 
Drug susceptibility pattern of S. paratyphi A [n(%)].
Year Total No. of isolates Ampicillin Chloramphenicol Cotrimoxazole Ciprofloxacin Ceftriaxone
2006 37   34 (92)    36 (97.3)   20 (54)   33 (89)   34 (92)
2007 35   34 (97) 34 (97)     35 (100)   19 (54)   34 (97)
2008 29     29 (100)   29 (100)    29 (100)     4 (14)     29(100)
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parts of India[11-13] . Adverse impact of nalidixic acid 
resistant S. typhi (NARST) strains, with longer duration of 
fever, higher frequency of hepatomegaly and elevated liver 
enzymes with increased MIC of ciprofloxacillin have been 
reported[14]. The global emergence of multidrug resiatant 
strain with decreased susceptibility to fluoroquinolones with 
poor clinical response despite disk sensitivity was reported 
by Bhan MK et al in 2005[15]. Multi drug resistant Salmonella 
enterica serotype Typhimurium associated with pet rodents 
was reported[16]. The resistance to quinolone is due to an 
altered DNA gyrase subunit. Indiscriminate use of drugs is 
one of the important factors leading to drug resistance and in 
case of ciprofloxacin, moderate cost, advantage of oral route, 
convenient dosage schedule, tolerability have contributed 
towards its indiscriminate use. Improved standards of public 
health have resulted in a marked decrease in the incidence 
of typhoid fever in developed countries[1], whereas in 
developing countries with poor water and sanitation system, 
practices treatment of enteric fever is a great challenge 
to modern medicine. Azhithromycin and third generation 
cephalosporins are the drugs of choice for enteric fever, but 
reports by Slinger et al. showed an incomplete response 
to cephalosporins[17]. Emergence of ciprofloxacin resistant 
isolates have allowed the extensive use of cephalosporins in 
the treatment of enteric fever in recent years. We have noted 
an increase in cases of paratyphoid fever in recent years 
in our hospital which might be due to increased laboratory 
confirmation of cases. The antimicrobial susceptibility has 
changed over the period of 3 years with increasing resistance 
to ciprofloxacin from 2006 to 2008, and sensitivity to first line 
drugs have shown an avenue for therapy with these drugs 
in uncomplicated cases, under the guidance of appropriate 
susceptibility results. However in rural India, where general 
population do not have an access to tertiary care hospital 
with laboratory facilities, most of the cases of suspected 
enteric fever are treated with empirical antibiotics. Recently 
we are seeing many cases of fever with features of enteric 
fever responding to cephalosporins, sometimes requiring 
addition of azithromycin but culture being repeatedly 
sterile due to the prior use of antibiotics by the general 
practitioners before referring the patients. Poor patient 
compliance, improper and inadequate dosages of antibiotics 
have contributed to emergence and spread of resistant 
isolates in the community. It is not a surprise in future if we 
see more cephalosporin resistant isolates. 
  In conclusion, though paratyphoid fever is relatively 
milder compared to typhoid fever, our findings highlight 
the importance of changing trends in susceptibility pattern 
of isolates. Since there is no effective vaccination against 
S. paratyphi A, we also reiterate the fact that public health 
interventions are constantly needed in educating general 
population about safe drinking water, food and personal 
sanitation measures. Antibiotics should be used cautiously 
according to susceptibility pattern and indiscriminate use 
should be discouraged.
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